A symposium, sponsored by the Cancer Research Campaign, was held recently at The Beatson Institute for Cancer Research in Glasgow to discuss cellular, molecular and clinical aspects of squamous cell carcinoma (SCC). The meeting was organised into five general topics:
(i) Epidermal organisation (ii) Carcinogenesis (iii) Signal transduction (iv) Invasiveness and metastasis (v) Immune response and therapy. Exciting aspects of the meeting were the identification of novel molecules involved in the malignant process as well as potential diagnostic/prognostic markers or targets for immunological and pharmacological intervention. It is these aspects of the symposium that will be highlighted in this report.
Stem cells
The predicted target cells for malignant transformation of the epidermis are the basal stem cells, since only these cells are mitotically active and consequently susceptible to the effects of chemical carcinogens. It has long been thought that the region of the epidermal lining of the hair follicle in which the stem cells are situated is an area at the base of the follicle known as the bulb region. However, Robert Lavker (New York) provided convincing proof that the stem cells are actually located in the bulge region of the upper root sheath. These cells are normally very slow-cycling, but during the anagen phase of hair growth they undergo transient proliferation. Interestingly, it is during anagen that the hair follicle is particularly susceptible to chemical carcinogenesis and cells from the bulge region grow better in culture than cells from other areas, including the bulb. Taken together these experiments have probably identified the true stem cell population of the hair follicle and should have important implications in the design and analysis of future skin chemical carcinogenesis experiments.
Cell adhesion molecules and small cell carcinoma (SSC) A recurring issue during the meeting was the role of cell adhesion molecules in the development of cancer. It is clear that these molecules are important in tissue organisation as well as in various stages of malignant progression including invasion and metastasis.
Once an epithelial cell leaves the basal stem cell layer it no longer divides but begins to terminally differentiate. Natural infection with human papillomaviruses (HPVs) induces benign proliferative lesions of epithelial surfaces which, in immunocompetent individuals, normally regress. Understanding the immunobiology of HPV infection is vital for the development of prophylactic or therapeutic intervention strategies. Margaret Stanley (Cambridge) described an animal model for studying the immunological events which occur during spontaneous rejection of HPV-16-induced warts. The technique involves grafting keratinocytes expressing HPV-16 oncogenes onto the backs of immunocompetent host mice. The grafts grow as differentiated epithelia and naturally regress after about 2 weeks. The regression can be accelerated by challenging the mice specifically with E7 antigen in what appears to be a delayed-type hypersensitivity response mediated by CD4+ cells. Since regression of human cutaneous warts is accompanied by infiltration of CD4+ lymphocytes, the presentation of HPV antigen by the epithelial route employed in these studies appears to provide an accurate model in which the immunobiology of HPV infection can be dissected and which may be of use in the development of immunotherapeutic vaccines against HPVinduced cancer.
Perhaps the most exciting prospect for immunotherapy of cancer is adoptive transfer of cytotoxic T cells (CTLs). CTLs recognise peptide sequences presented by MHC class 1 molecules on the surface of all cells, and in combination with interleukin 2 (IL-2) they have been shown to eradicate large tumour masses in mice. CTLs can be cultured from tumour infiltrating lymphocytes; however, some tumours are poorly immunogenic, and this procedure may not always work. Cornelis Melief (Leiden) presented an attractive alternative approach to this problem. Empty MHC -class I molecules expressed on the surface of murine mutant lymphoma cells can be stabilised by presenting them with peptides. This system allows for the identification of T-cell epitopes within a protein of choice and also the sensitisation of target T cells for use in immunotherapy. Using overlapping peptides corresponding to the HPV-16 E7 oncoprotein an E7 peptide sequence has been identified that stimulates a T-cell response, and immunisation with this peptide protects mice from tumour formation when challenged with HPV-expressing tumour cells.
Clearly this technique has enormous potential in the immunotherapy of virally induced disease as well as cancers of varying origins. CTLs have now been generated from peptides derived from various oncogenic proteins, including p53 and ras, and their therapeutic potential, although enormous, remains to be shown.
Potential therapeutics
As mentioned earlier in this report, treatment of tumour metastasis is vital if effective anti-cancer regimens are to be achieved. A crucial property of invading tumour cells is the ability to degrade the ECM and underlying basement membrane. Many proteases have been implicated in tumour invasion, one class of which, the metalloproteases, was the subject of Mark Sobel's (Bethesda) presentation. Metalloproteases are synthesised as proenzymes and are activated by proteolytic cleavage, which removes an inhibitory peptide. Their activity is further regulated by specific inhibitory molecules, tissue inhibitors of metalloproteases (TIMPs), of which two family members have been identified, and these have different substrate specificities. TIMP-1 and -2 are able to inhibit tumour metastasis in several model systems and, therefore, provide potential molecules upon which antimetastasis agents can be designed.
A potential anti-cancer therapy that is already in clinical trial is based upon the blockade of the epidermal growth factor receptor (EGFR), which has been shown to be overexpressed in many squamous cell tumours. John Mendelsohn (New York) has developed two monoclonal antibodies which bind EGFR with high affinity and block EGF binding and its resulting tyrosine kinase activity. Ligand-dependent 
